Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chronic obstructive pulmonary disease

J Mark Madison, Richard S Irwin

Acute exacerbations of underlying COPD are a common cause of respiratory deterioration. Developments have been made in preventive measures, but admission to hospital for acute exacerbations can be expected to remain common. Several expert consensus guidelines have been published to define the appropriate management of COPD patients. These consensus guidelines generally agree, but all acknowledge a lack of large well-controlled clinical studies, especially studies focusing on the management of acute exacerbations. Consequently, many potential controversies exist about the details of managing patients with acute exacerbations. Although studies of many fundamental aspects of management are still needed, the results of controlled clinical trials are sufficient to emphasise the importance of a careful clinical assessment, supplemental oxygen, inhaled bronchodilators to partially improve airway obstruction, corticosteroids to decrease the likelihood of treatment failures and to speed recovery, antibiotics, especially in severe patients, and non-invasive positive-pressure ventilation for treatment of acute ventilatory failure in selected patients.

Chronic obstructive pulmonary disease (COPD) is a major medical problem. In the USA, COPD is the fourth main cause of death. Although established risk factors include occupational exposures and hereditary \( \alpha_1 \)-antitrypsin deficiency, cigarette smoking is the most important risk factor. Only 15–20% of smokers, however, develop clinically important chronic airflow obstruction; why the proportion is so small is not known, but underlying host factors may play a part.

There has not yet been a precise agreement on a definition of COPD. The American Thoracic Society defines COPD as a disease process featuring progressive chronic airflow obstruction due to chronic bronchitis, emphysema, or both. The obstruction to airflow may be partly reversible and some patients may manifest bronchial hyper-responsiveness. Excluded from this definition is asthma, which may also cause chronic airflow obstruction and may be difficult to distinguish from COPD in some cases. Although this definition of COPD well describes common usage, the emphasis on the term chronic bronchitis may not be ideal. Chronic bronchitis is defined clinically by the hypersecretion of mucus, which occurs mainly in large airways, not the site of the progressive chronic airflow obstruction. It has been suggested that a definition of COPD should emphasise the central pathogenic role of an inflammatory process that progressively leads to obstruction by causing fibrosis and distortion of terminal airways, loss of alveolar attachments that tether small airways, hypersecretion of mucus, and contraction of smooth muscle.

For stable COPD, when the patient is either symptom-free or has symptoms without substantial fluctuation, management should aim to improve the quality of life by relieving symptoms, preventing acute exacerbations, and by slowing progressive deterioration in lung function.

Guidelines for comprehensive management of stable COPD have been published. Since patients with stable COPD have limited baseline respiratory function, they are at higher risk of developing respiratory failure from respiratory insults, such as pneumonia, congestive heart failure, and pulmonary thromboembolism. There is, however, no widely established definition of acute exacerbations of COPD among the most common causes of acute respiratory deterioration in patients with COPD. The term acute may indicate any respiratory deterioration due to various causes in underlying COPD. Such a non-specific definition creates difficulties for the interpretation of clinical studies and is not especially helpful to the clinician. We define an acute exacerbation of COPD as an acute tracheobronchitis, generally infectious in aetiology, that occurs in a patient with established COPD. An important element of this definition is that other causes of respiratory deterioration in a patient with COPD such as congestive heart failure, cardiac arrhythmias, pneumothorax, pneumonia, and pulmonary thromboembolism must be excluded.

The exacerbation of COPD is typically manifested by combinations of increased dyspnoea, wheezing, cough, sputum production, and worsened gas exchange. Most patients with exacerbations are managed as outpatients, but admission to hospital is often required for close monitoring and treatment. We focus on the inpatient management of acute exacerbations of COPD.

Prevention of acute exacerbations

The clinical course of COPD is intermittently interrupted by acute exacerbations, especially during the winter months. In one study, 173 patients had a mean of 1–3 exacerbations per year (range 0–9.6). Prevention or attenuation of the severity of exacerbations is an important goal in the management of stable COPD. Education of patients, the stopping of smoking, pulmonary rehabilitation, nutrition, and early medical intervention when symptoms worsen all help to prevent exacerbations. The value of pneumococcal vaccine in COPD is still debatable, but influenza and...
Treatment of acute exacerbations of COPD

| Disorder | Therapy | Strength of recommendation | Comments |
|----------|---------|----------------------------|----------|
| Bacterial infection of airways | Antibiotics | ++ | Benefits supported by R/PC and R/DB/PC trials, especially for severe exacerbations |
| Airway inflammation | Corticosteroids | +++ | Benefits supported by R/DB/PC trials may also decrease airway secretions |
| Bronchoconstriction | Aerosolised-adrenergic agonist | +++ | Metered-dose inhaler/spacer equal to wet nebuliser in R/DB trials |
| | Aerosolised ipratropium | +++ | Maximum effect same as β-adrenergic agonists but slower onset in R/DB trials |
| | Combined β-adrenergic agonist | ++ | Combination therapy more effective than single agents in stable COPD |
| | Theophylline + other bronchodilator | – | R/DB/PC trial shows no advantage in adding theophylline to otherwise standard therapy |
| Secretions | Stop smoking | +++ | By consensus, generally recommended |
| | Expectorants, iodides, DNase | – | By consensus, no proven value in acute setting |
| | Hydration in excess of euvalaemia | – | By consensus, no proven value in acute setting |
| | Chest physiotherapy | – | By consensus, no proven value in acute setting; may be useful in select patients |
| Impaired gas exchange and acute ventilatory failure | Supplemental oxygen (titrated) | +++ | By consensus; decreases pulmonary vasoconstriction and improves end-organ function |
| | Treat comorbid disorders that impair gas exchange | +++ | By consensus eg, pneumonia, congestive heart failure, pulmonary embolism, pneumothoraces |
| | Treat comorbid disorders that impair muscle function | +++ | By consensus eg, splintering from rib pain or vertebral fracture, oversedation, malnutrition |
| | Doxapram | + | By consensus’ possibly useful in selected patients |
| | Non-invasive assisted ventilation | +++ | Risk of intubation decreased in carefully selected patients (further reading) |
| | Intubation and mechanical ventilation (when indicated) | +++ | By consensus monitor to keep dynamic hyperinflation and auto-PEEP to minimum |

MDI = metered-dose inhaler; PEEP = positive end-expiratory pressure. ·· = not recommended; ++ = strong recommendation; +++ = moderate recommendation; ++++ = weak recommendation; R = randomised; DB = double-blind; PC = placebo-controlled. *Gradation based on perceived strength of best evidence or by expert consensus. † Specific for patients in hospital.

Assessment

An exacerbation typically includes increased cough, changes in volume, tenacity, and purulence of sputum, and increased breathlessness, wheezing, and chest tightness. In some cases, however, cough may be so ineffective because of severe airway obstruction that increased sputum production is not apparent. In initial assessment of COPD patients with respiratory deterioration, clinicians should look for evidence of comorbid disorders causing or contributing to respiratory deterioration, and review medications such as sedatives or β-adrenergic antagonists. Finally, acute exacerbations of COPD are only one of many causes of a cough-phlegm syndrome (others include postnasal-drip syndrome, sinusitis, asthma, and gastro-oesophageal-reflux disease), and, therefore, increased cough or sputum production alone in a patient with COPD may not indicate an exacerbation.

History, physical assessment, and arterial blood gases are used to assess the severity of the exacerbation and to judge whether the patient requires admission to hospital. On physical assessment, particular attention should be paid to changes in mental status, use of accessory muscles of respiration, and paradoxical abdominal breathing, since any of these findings suggests respiratory failure. Arterial blood gases are also an important assessment tool, but exact values of arterial partial pressures of oxygen (PO₂) and carbon dioxide (PCO₂) do not define acute respiratory failure since patients with COPD have various baseline values. Instead, changes must be interpreted relative to baseline values and in conjunction with symptoms. Generally, however, an arterial PO₂ of less than 7.3 kPa or a PCO₂ of more than 6.7 kPa with an accompanying acute or acute-on-chronic respiratory acidosis, show acute respiratory failure and are clear indications for admission to hospital. In the absence of acute respiratory failure, admission to hospital should be judged on ability to manage daily activity at
home, the speed of worsening symptoms or gas exchange abnormalities, response to initial therapy, the patient’s home setting, access to follow-up, and the severity of the patient’s baseline airway obstruction.\textsuperscript{15,16} Unlike assessment of asthmatics, the role of spirometry or peak-flow measurements to assess the need for emergency admission to hospital has not been established. Most studies have found a poor correlation between spirometric values alone and successful discharge from the emergency room.\textsuperscript{14,15} The potential application of spirometric measurements in the acute setting is an important issue because lack of specific criteria for admission undoubtedly contribute to the fact that at least 17–28% of COPD patients discharged from emergency departments ultimately require admission to hospital.\textsuperscript{14,16}

The goals of admission to hospital are to relieve airway obstruction, correct hypoxaemia, and to address any comorbid disorders (eg, congestive heart failure or pneumonia) that may also contribute to respiratory deterioration (table).\textsuperscript{2,3} Patients with exacerbations are generally medically ready for discharge when they are clinically stable off parenteral therapy for 12–24 h, require inhaled bronchodilators no more than every 4 h, have stable arterial blood gases for 12–24 h, are able to walk at least short distances, and have follow-up arranged. One expert consensus guideline recommends routinely following up peak expiratory flow twice daily in patients staying in hospital to assess progress;\textsuperscript{2} however, the clinical value of this approach has not been established and other guidelines do not specifically recommend the practice.\textsuperscript{2,3}

**Antibiotic therapy**

Although non-infectious causes of exacerbations may be important (eg, pollution or inhaled irritants), the major precipitants of exacerbations of COPD are acute airway infections.\textsuperscript{17} The infection and consequent inflammatory response by the host leads to increased airway obstruction. At least a third of exacerbations may be caused by viral infections.\textsuperscript{18} In one study of 186 patients, rhinoviruses, influenza virus, parainfluenza virus, and coronavirus were significantly associated with acute exacerbations of COPD.\textsuperscript{19} Patients did not seem to have increased susceptibility to these viruses, but viral infections did have more serious consequences in COPD patients.

The role of bacteria in precipitating exacerbations is controversial. Bacteria may have a primary role in the development of an exacerbation or represent a secondary superinfection of an initial viral process.\textsuperscript{17} The controversy stems partly from the presence of various bacterial species in the airways of 25–50% of patients, even when the COPD is stable.\textsuperscript{16,20} A role for bacterial infection has been suggested when there is an abundance of neutrophils in sputum,\textsuperscript{21} and the fact that bacteria are more often recoverable during acute exacerbations compared with in stable COPD\textsuperscript{16} support roles. The major bacterial organisms that have been associated with exacerbations are *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella (Branhamella) catarrhalis*.\textsuperscript{16} *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* may play a part.\textsuperscript{16,22} Evidence also suggests that during acute exacerbations in patients with a baseline forced expiratory volume in 1 s (FEV\(_1\)) of 35% or less predicted, gram-negative bacteria, especially *Enterobacteriaceae* and *Pseudomonas*, spp play an important part in acute exacerbations.\textsuperscript{23}

The effects of antibiotics also suggest an aetiological role for bacteria in exacerbations in some patients. A meta-analysis of nine studies showed a small overall benefit with antibiotic treatment for COPD exacerbations.\textsuperscript{24} The largest study included 362 exacerbations in 173 outpatients.\textsuperscript{7} Compared with placebo, the rate of symptom resolution and improvement of peak expiratory flow during exacerbations was slightly but significantly faster when patients were treated with co-trimoxazole, amoxicillin, or doxycycline. For example, when patients received no antibiotics, mean peak expiratory flow increased from 190 L/min to 210 L/min in 9 days. When these antibiotics were used during exacerbations, the same improvement in peak expiratory flow was seen in only 6 days. More importantly, treatment failures, defined by respiratory deterioration, were nearly twice as likely in the placebo group. Benefit from antibiotics was most evident for patients with the most symptoms (dyspnoea, increased sputum volume, and sputum purulence) and there was a trend in the favour of antibiotics when corticosteroids were used.

Although viral infections probably account for many exacerbations of COPD, bacterial infections do have an aetiological role in some exacerbations in some patients. Many clinicians use antibiotics to treat exacerbations, especially when patients have at least two of increased dyspnoea, increased sputum volume, and sputum purulence.\textsuperscript{7} For patients admitted to hospital with acute exacerbations of COPD, the rationale for antibiotic treatment is that: antibiotics are most helpful in patients with the worst symptoms; antibiotics substantially decrease rate of treatment failures when patients have little margin for respiratory deterioration; slightly increase the rate of recovery; the risks of side-effects from antibiotics are low; and an aetiological role for bacteria in individual cases cannot be excluded. Inexpensive antibiotics, amoxicillin, co-trimoxazole, or doxycycline, are generally selected for treatment of outpatients. If resistant organisms are suspected or when the severity of the patient’s clinical condition puts them at high-risk of treatment failure, a second or third generation cephalosporin, fluoroquinolone, newer macrolide, or broad-spectrum penicillin may be preferred.\textsuperscript{23,25,26} Studies are needed to select patients who will benefit from antibiotics, show optimum antibiotic choices given local and changing resistance patterns, establish the duration of antibiotic therapy, and test the hypothesis that recurrent infections have a role in progression of COPD.

**Anti-inflammatory therapy**

The acute inflammatory response to infections of the airways stimulates mucus hypersecretion, airway-wall oedema, and smooth-muscle contraction. Abundant neutrophils in sputum suggests a primary or secondary bacterial infection.\textsuperscript{21} One study has shown that sputum sampled during acute exacerbations typically had a greater increase in eosinophils than neutrophils, and bronchial biopides showed substantial airway eosinophilia with a small increase in neutrophils and activated T lymphocytes.\textsuperscript{27} Although there is always the question of how well asthmatics are excluded from a
study such as this, the eosinophilic inflammation seemed to be different from that seen in asthmatics since expression of interleukin 5 was not seen during exacerbations of COPD.7

Theoretically, corticosteroids could decrease such airway inflammation in COPD. One study showed that severely obstructed patients treated with intravenous methylprednisolone had more rapid improvement of FEV1, over the first 72 h of a stay in hospital than patients not given corticosteroids.8,9 The absolute differences between the groups were small, with increases in FEV1 of about 0.240 mL in the methylprednisolone group and only 0.135 mL in the placebo group. The study did show, however, that 12 of 22 patients who received methylprednisolone had more than a 40% improvement in FEV1, after 72 h, but only three out of 21 patients on placebo had similar improvements. Another study of 27 outpatients assessed the effects of corticosteroids on exacerbations of COPD and found that corticosteroids slightly increased the rate of improvement in oxygenation and spirometry and decreased the treatment failure rate.10 Of those 14 patients treated with placebo, eight had no improvement in symptoms or required admission to hospital. For patients treated with prednisolone, none of 13 had treatment failure. A different study of 30 patients suggested that corticosteroids significantly decreased the rate of relapse from 33.3% to 8.9% in the first 48 h after discharge from the emergency department.10 Finally, data from the Systemic Corticosteroids in COPD Exacerbations clinical trial support the use of corticosteroids in patients admitted to hospital for acute exacerbations of COPD.11 In that trial, patients treated with systemic corticosteroids had fewer treatment failures, better spirometry, and shorter hospital stays. Based on all such evidence, patients admitted to hospital for COPD exacerbations commonly receive systemic corticosteroids. The rationale is that although the favourable effect of corticosteroids is modest, even a small improvement is beneficial in patients with severe airway obstruction who cannot tolerate further respiratory deterioration. Additional studies are needed to find the optimum dose and duration of corticosteroid therapy during acute exacerbations. Importantly, the resolution of an acute exacerbation after corticosteroids for 7–14 days should not be taken as an indication for chronic systemic-corticosteroid therapy.

Bronchodilator therapy

Obstruction to airflow results in increased respiratory work, hyperinflation that places the respiratory muscles at mechanical disadvantage, and impaired ventilation-perfusion matching that causes hypoxaemia. Therefore, relief from airflow obstruction to prevent or correct respiratory failure is a major goal in the treatment of acute exacerbations.

Relief from bronchoconstriction is the most rapid means of improving airway resistance, and the improved airflow may help to make cough more effective in clearing secretions. Unfortunately, bronchoconstriction is generally not the only or major cause of airway obstruction during an exacerbation of COPD, and, therefore, the immediate effects of bronchodilation are often only slight. Small improvements in airflow may, however, benefit patients with severe airflow obstruction; therefore, rapidly acting β-2-adrenergic agonists delivered by aerosol are the mainstay of initial treatment. In one typical study, inhaled orciprenaline increased the FEV1 from about 0.69 L to 0.93 L in 30–60 min.12 Evidence suggests that metered-dose inhalers with spacers are as effective as wet nebulisation for delivery of β-adrenergic agonists.13

Ipratropium bromide, an anticholinergic delivered by inhalation, has been used to treat acute exacerbations. As a single agent, the effects of ipratropium on spirometry are at least equal to the slight effects of β-adrenergic agonists, possibly with less risk of decreased blood oxygenation. Patients with exacerbations of COPD on inhaled ipratropium had a small but significant increase (0.8 kPa) in arterial PO2 within 30 min. By contrast, with inhaled metaproterenol there was a transient decrease (0.8 kPa) in arterial PO2.32 This decrease in arterial PO2 after β-adrenergic agonists has been attributed to transient worsening of ventilation-perfusion matching because of vasodilation of the pulmonary vasculature, or increases in cardiac output, or both. Since the rate of onset for bronchodilation is slow with ipratropium (peak effect 60–90 min), many physicians prefer β-adrenergic agonists as the first-line bronchodilator during acute exacerbations. In practice, β-adrenergic agonists and ipratropium are frequently combined to treat exacerbations, especially when patients respond poorly to therapy. Extrapolation from studies of patients with stable COPD support combination therapy, but at least one study of acute exacerbations did not show any benefit from the combination of these agents.32

The roles of the bronchodilators theophylline or intravenous aminophylline have diminished because of toxic effects and little proof of efficacy when combined with other bronchodilators. One study showed that aminophylline added no benefit to standard treatment of acute exacerbations of COPD.33 Another showed a non-significant trend in favour of aminophylline.34 The drug is now used mainly if inhalational agents cannot be given.

Clearance of secretions

After airways are opened and the inflammatory response that promotes mucus hypersecretion and bronchoconstriction has decreased, bronchodilators, antibiotics, and corticosteroids all help to relieve airway obstruction by decreasing tracheobronchial secretions. Additionally, β-adrenergic agonists may stimulate mucociliary clearance.35 Besides the pharmacological measures, cigarette smoking should be stopped because the irritant effects of smoke may stimulate mucus secretion, promote airway inflammation, and impair mucociliary clearance. The teaching of “huff coughing” may help patients to clear secretions.37 Other measures to improve clearance of mucus during exacerbations (eg, expectorants and mucolytics such as N-acetylcysteine, iodides, guaifenesin, and DNase) have limited proven value.38 Unless more than 25 mL of sputum is produced per day or there is mucus plugging with lobar atelectasis, chest physiotherapy has no proven value during exacerbations.2,27 Nasotracheal suctioning has been used to help some patients clear secretions but the technique has serious risks, and we believe that safer alternatives should be used.38 Similarly, bland aerosol therapy, and systemic hydration in excess of euvoalaemia have no proven role in the treatment of COPD.

470 THE LANCET • Vol 352 • August 8, 1998
Supplemental oxygen therapy
During exacerbations, hypoxaemia is caused mainly by worsened ventilation-perfusion matching. As airway obstruction becomes more severe and the duration lengthens, respiratory muscles may be unable to sustain breathing. Alveolar hypoventilation contributes to further hypoxaemia, hypercarbia, and respiratory acidosis. Hypoxaemia and respiratory acidosis promote pulmonary vasoconstriction that, in turn, causes high pulmonary-artery pressures, which imposes an added load on the right ventricle of the heart. When right-ventricular failure complicates exacerbations of COPD, supplemental oxygen, diuretics, but not digitalis, can improve function. Severe hypoxaemia and hypercarbia with respiratory acidosis may also compromise left-ventricular function, precipitate arrhythmias, impair respiratory muscles, and depress mental status.

Correction of hypoxaemia to achieve an arterial oxygen tension of at least 7·3–8·0 kPa is the immediate priority of management of patients admitted to hospital for acute exacerbations of COPD and specific recommendations for stepwise controlled correction of hypoxaemia have been made in guidelines. In many cases, low-flow oxygen administered by nasal prongs (1–2 L/min) or venturi-type facial masks (28%) is sufficient. Administration of oxygen is carefully controlled and arterial blood gases are serially monitored because, in a few patients, arterial PCO₂ may increase and an acute respiratory acidosis occur. Patients developing an arterial pH of less than 7·26 when supplemental oxygen is delivered have a significantly poorer outlook. The mechanism underlying the acute increase in arterial PCO₂ that occurs in some patients is not clear. Emphasis has previously been placed incorrectly on supplemental oxygen therapy causing hypercapnia because of depressed hypoxic drive to breathe in patients with COPD. Most evidence now suggests that minute ventilation and drive to breathe do not decrease with supplemental oxygen. The rise in arterial PCO₂ after administration of supplemental oxygen, is probably due to the Haldane effect and worsening ventilation-perfusion matching.

Assisted ventilation
Neuromuscular function may be unable to meet or sustain the increased work of breathing imposed by increased obstruction to airflow. Impaired neuromuscular function by depressed consciousness and fatigue or weakness of respiratory muscles can contribute to acute ventilatory failure during exacerbations of COPD. Therefore, correction of factors that impair respiratory neuromuscular function is important, such as electrolyte disturbances, pain-causing splinting, abdominal distension or ascites, poor nutrition, and any sedating drugs that are contraindicated unless the patient is receiving assisted ventilation. The use of the respiratory-muscle stimulant doxapram to increase alveolar ventilation in acute ventilatory failure may be beneficial. In one study, half as many patients treated with doxapram had increases in PCO₂ during the first 2 h after admission to hospital. No study has shown that doxapram decreases the need for assisted ventilation and use of this medication to treat patients with acute ventilatory failure has not been widely adopted.

Despite maximum medical therapy, some patients with exacerbations of COPD will have severe and progressive acute respiratory acidosis, severe hypoxaemia, or both, despite supplemental oxygen. Assisted ventilation provides short-term support while airway obstruction is treated. Evidence indicates that non-invasive positive-pressure assisted ventilation is useful for severely ill patients who do not require immediate endotracheal intubation. Mechanical ventilation, with its potential complications of barotrauma and infection, can then be avoided. The best time to start non-invasive mechanical ventilation is not established, but early intervention if the respiratory rate is more than 30 breaths per min and the pH is less than 7·35 has been suggested. Successful non-invasive positive-pressure assisted ventilation should improve respiratory rate and pH within 1 h. Positive pressure via a tight-fitting facial or nasal mask lessens the work of breathing, which may allow recovery of fatigued respiratory muscles. Interestingly, even brief periods (6–8 h/day) of non-invasive support seem to decrease the risk of an eventual need for intubation. This technique is recommended only for tolerant and cooperative patients who are not sedated, are haemodynamically stable, able to protect their airways and clear secretions, and, importantly, are cared for by intensive-care support staff familiar with non-invasive support. This technique will probably become an increasingly popular short-term intervention for select patients.

The decision to intubate and initiate mechanical ventilation is complex; each patient’s baseline quality of life is an important consideration (panel). Notably, the absolute value of arterial PCO₂ alone should not be used to indicate the need for intubation since many patients with severe COPD may have a baseline compensated respiratory acidosis and do not require assisted ventilation. Arterial PCO₂ must be assessed in relation to arterial pH. When patients do require intubation and mechanical ventilation for exacerbations, they should be supported with positive-pressure ventilation with assist-control, intermittent-mandatory, or pressure-support, ventilatory methods. Pressure-support ventilation may be more comfortable for patients but outcomes have not been shown to be different from the other methods. The major complications of invasive positive-pressure ventilation are barotrauma, pneumonia, and local complications of endotracheal tubes. Risk of barotrauma is decreased by keeping the autopositive end-expiratory pressure to a minimum.

General management
We practise the following general-management plan. For inpatient treatment of acute exacerbations of COPD, assessment begins with clinical assessment and measurement of arterial blood gases for evidence of respiratory failure that needs assisted ventilation. We
identify comorbid illnesses, such as pneumonia, and medications that could contribute to respiratory deterioration. Various treatments are started. Controlled low-flow, supplemental oxygen is delivered to achieve and maintain an arterial PO$_2$ of at least 7.3–8.0 kPa. Delivery of oxygen by nasal prongs is generally preferred to mask delivery because prongs are more comfortable and patients are more likely to leave them in place. Arterial blood gases are measured serially when patients are on supplemental oxygen to ensure that they are not among the minority who develop respiratory acidosis upon delivery of oxygen. We administer a broad-spectrum antibiotic. For patients admitted to hospital with severe airflow obstruction at high risk of treatment failure, we generally select a second-generation cephalosporin, fluoroquinolone, or second-generation macrolide. Bronchospasm is treated and mucociliary clearance possibly improved with inhaled $\beta$-adrenergic agonists, given by metered-dose inhaler and spacer under direct supervision. For patients with severe or rapidly progressive deterioration and only a slight response to $\beta$-adrenergic agonists, ipratropium by inhalation every 4–6 h is added. Patients are started on intravenous methylprednisolone and changed to prednisolone after 1–3 days when clear improvement is seen. To help mobilise secretions, patients are encouraged to cough while sitting upright in a chair, and early ambulation is encouraged. Chest physiotherapy is not done routinely since evidence is insufficient to show any value in acute exacerbations. Throughout treatment, patients undergo frequent clinical assessments, and arterial blood gases and oximetry are monitored to assess response to therapy. For patients who have severe and worsening symptoms of respiratory acidosis despite therapy, or who have hypoxaemia on supplemental oxygen, assisted ventilation is used (panel). For select patients, non-invasive ventilation is preferred.

Any general approach to acute exacerbations of COPD must acknowledge the lack of large, double-blind, placebo-controlled clinical trials addressing fundamental questions of management. Comprehensive, widely accepted, evidenced-based guidelines for management do not yet exist. Expert consensus guidelines do, however, agree on many issues.\textsuperscript{2,3,6}

Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980; 121: 225–32.

3. Siafakas NM, Vermeire P, Pride NB, et al, on behalf of the Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398–420.

4. Siafakas NM. ERS consensus statement: optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir Rev 1996; 6: 270–75.

5. Saetta M. Airway pathology of COPD compared with asthma. Eur Respir Rev 1997; 45: 211–15.

6. Pearson MG, Alderslade R, Allen SC, et al. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl 5): S51–28.

7. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Center for Disease Control. Recommendations of the immunization practices advisory committee, American Lung Association/American Thoracic Society, April 24–29, 1998, Chicago, Illinois.

8. Thompson WH, Nielsen CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–12.

9. Murata GH, Gorbry MS, Chick TW, Halperin AK. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD. Chest 1998; 103: 845–49.

10. Erland NL, Niewoehner D. Results from SCCOP: systemic corticosteroids in COPD exacerbations trial. Presented at the International Conference for American Lung Association/American Thoracic Society, April 24–29, 1998, Chicago, Illinois.

11. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1997; 111: 241–47.

12. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Am Rev Respir Dis 1980; 92: 753–58.

13. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Chest 1996; 109: 73–80.

14. Collet JP, Shapiro S, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1719–24.

15. Allegre L, Cordaro CI, Grusci C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respir 1996; 63: 174–80.

16. Regine JE, Bast A, Lankhorst I, and The Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995; 152: 577–120.

17. Siafakas NM, Vermeire P, Pride NB, et al, on behalf of the Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398–420.

18. Saetta M. Airway pathology of COPD compared with asthma. Eur Respir Rev 1997; 45: 211–15.

19. Pearson MG, Alderslade R, Allen SC, et al. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl 5): S51–28.

20. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995; 152: 1316–20.

21. Saetta M. Airway pathology of COPD compared with asthma. Eur Respir Rev 1997; 45: 211–15.

22. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Resp J 1993; 6: 19–22.

23. Eller J, Ede A, Scaberg T, et al. Infective exacerbations of chronic bronchitis. Chest 1998; 113: 1542–49.

24. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995; 273: 957–60.

25. Canadian Bronchitis Symposium. Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994; 151 (suppl): 5–23.

26. Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD. Chest 1998; 113: 2495–555.

27. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Resp Crit Care Med 1994; 150: 1646–52.

28. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Am Rev Respir Dis 1980; 92: 753–58.

29. Thompson WH, Nielsen CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Resp Crit Care Med 1996; 154: 407–12.

30. Murata GH, Gorbry MS, Chick TW, Halperin AK. Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD. Chest 1998; 103: 845–49.
36 Wanner A, Salathe M, O’Riordan TG. Muscular innervation in the airways. Am J Respir Crit Care Med 1996; 154: 1688–902.
37 Kirilloff LH, Owens GR, Rogers RM, Mazzocco MC. Does chest physical therapy work? Chest 1985; 88: 1436–44.
38 Irwin RS, French CT, Mike RW. Respiratory adjunct therapy. In: Rippe JM, Irwin RS, Fink MP, Cerra FB, eds. Intensive care medicine, 3rd edn. Boston: Little, Brown and Co, 1996: 773–86.
39 Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. Thorax 1992; 47: 34–40.
40 Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 121: 717–54.
41 Newman SL, Rousos CS. Function and failure of the ventilatory muscles. In: Simmons DH, ed. Current pulmonary medicine, vol 7. Chicago: Year Book Medical Publishers, 1986: 272–301.
42 Moser KM, Luchinger PC, Adamson JS, et al. Respiratory stimulation with intravenous doxapram in respiratory failure. N Engl J Med 1973; 288: 427–31.
43 Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive pulmonary disease. Lancet 1993; 341: 1555–57.
44 Brochard L, Mancofo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22.
45 Hillberg RE, Johnson DC. Noninvasive ventilation. N Engl J Med 1997; 337: 1745–52.
46 Elliott MW. Noninvasive ventilation in chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 870–71.

Further reading

Epidemiology
American Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis 1976; 113: 490–511.

Anthonisen N. Epidemiology and the Lung Health Study. Eur Respir Rev 1997; 7: 202–05.

Buist AS. Risk factors for COPD. Eur Respir Rev 1996; 39: 253–58.

Davis RM, Novotny TE. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 582–84.

Snedler GL, Kleineman J, Thurbeck WM, Bengali ZK. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of Lung Diseases, Workshop. Am Rev Respir Dis 1985; 132: 182–85.

Pathology and pathophysiology
Jeffry PK. Pathology of asthma and COPD: a synopsis. Eur Respir Rev 1997; 7: 111–18.

Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.

Pare PD, Bai TR. Airway wall remodeling in chronic obstructive pulmonary disease. Eur Respir Rev 1996; 6: 259–63.

Rennard S. Pathophysiological mechanisms of COPD. Eur Respir Rev 1997; 7: 206–10.

Sandford AJ, Pieterse DJ. Auto-PEEP during mechanical ventilation: a reevaluation. Crit Care Med 1988; 16: 266–70.

Stockley RA. New perspectives on the protease/antiprotease balance. Eur Respir Rev 1997; 7: 128–30.

Prevention
Clancy R, Cripps A, Murrell-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. J Med 1995; 344: S139–47.

Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis of efficacy of immunisation with killed Haemophilus influenzaefor protection against acute bronchitis in chronic obstructive lung disease. Am J Respir Crit Care Med 1997; 156: S139–47.

Snedler GL, Kleineman J, Thurbeck WM, Bengali ZK. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of Lung Diseases, Workshop. Am Rev Respir Dis 1985; 132: 182–85.

Pathology and pathophysiology
Jeffry PK. Pathology of asthma and COPD: a synopsis. Eur Respir Rev 1997; 7: 111–18.

Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.

Pare PD, Bai TR. Airway wall remodeling in chronic obstructive pulmonary disease. Eur Respir Rev 1996; 6: 259–63.

Rennard S. Pathophysiological mechanisms of COPD. Eur Respir Rev 1997; 7: 206–10.

Sandford AJ, Pieterse DJ. Auto-PEEP during mechanical ventilation: a reevaluation. Crit Care Med 1988; 16: 266–70.

Stockley RA. New perspectives on the protease/antiprotease balance. Eur Respir Rev 1997; 7: 128–30.

Prevention
Clancy R, Cripps A, Murrell-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. J Med 1995; 344: S139–47.

Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis of efficacy of immunisation with killed Haemophilus influenzaefor protection against acute bronchitis in chronic obstructive lung disease. Am J Respir Crit Care Med 1997; 156: S139–47.

Snedler GL, Kleineman J, Thurbeck WM, Bengali ZK. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of Lung Diseases, Workshop. Am Rev Respir Dis 1985; 132: 182–85.

Pathology and pathophysiology
Jeffry PK. Pathology of asthma and COPD: a synopsis. Eur Respir Rev 1997; 7: 111–18.

Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.

Pare PD, Bai TR. Airway wall remodeling in chronic obstructive pulmonary disease. Eur Respir Rev 1996; 6: 259–63.

Rennard S. Pathophysiological mechanisms of COPD. Eur Respir Rev 1997; 7: 206–10.

Sandford AJ, Pieterse DJ. Auto-PEEP during mechanical ventilation: a reevaluation. Crit Care Med 1988; 16: 266–70.

Stockley RA. New perspectives on the protease/antiprotease balance. Eur Respir Rev 1997; 7: 128–30.

Prevention
Clancy R, Cripps A, Murrell-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. J Med 1995; 344: S139–47.

Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis of efficacy of immunisation with killed Haemophilus influenzaefor protection against acute bronchitis in chronic obstructive lung disease. Am J Respir Crit Care Med 1997; 156: S139–47.

Snedler GL, Kleineman J, Thurbeck WM, Bengali ZK. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of Lung Diseases, Workshop. Am Rev Respir Dis 1985; 132: 182–85.

Pathology and pathophysiology
Jeffry PK. Pathology of asthma and COPD: a synopsis. Eur Respir Rev 1997; 7: 111–18.

Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.

Pare PD, Bai TR. Airway wall remodeling in chronic obstructive pulmonary disease. Eur Respir Rev 1996; 6: 259–63.

Rennard S. Pathophysiological mechanisms of COPD. Eur Respir Rev 1997; 7: 206–10.

Sandford AJ, Pieterse DJ. Auto-PEEP during mechanical ventilation: a reevaluation. Crit Care Med 1988; 16: 266–70.

Stockley RA. New perspectives on the protease/antiprotease balance. Eur Respir Rev 1997; 7: 128–30.